Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9863660rdf:typepubmed:Citationlld:pubmed
pubmed-article:9863660lifeskim:mentionsumls-concept:C0007412lld:lifeskim
pubmed-article:9863660lifeskim:mentionsumls-concept:C0376579lld:lifeskim
pubmed-article:9863660lifeskim:mentionsumls-concept:C2003941lld:lifeskim
pubmed-article:9863660lifeskim:mentionsumls-concept:C1152726lld:lifeskim
pubmed-article:9863660lifeskim:mentionsumls-concept:C0033268lld:lifeskim
pubmed-article:9863660lifeskim:mentionsumls-concept:C0205227lld:lifeskim
pubmed-article:9863660lifeskim:mentionsumls-concept:C0205228lld:lifeskim
pubmed-article:9863660lifeskim:mentionsumls-concept:C0127400lld:lifeskim
pubmed-article:9863660lifeskim:mentionsumls-concept:C0441712lld:lifeskim
pubmed-article:9863660lifeskim:mentionsumls-concept:C0758515lld:lifeskim
pubmed-article:9863660pubmed:issue6lld:pubmed
pubmed-article:9863660pubmed:dateCreated1999-3-25lld:pubmed
pubmed-article:9863660pubmed:abstractTextNoradrenaline (NA) and adrenaline (Ad) are modulators of cytokine production. Here we investigated the role of these neurotransmitters in the regulation of macrophage inflammatory protein (MIP)-1alpha expression. Pretreatment of RAW 264.7 macrophages with NA or Ad decreased, in a concentration-dependent manner (1 nM-100 microM), MIP-1alpha release induced by bacterial lipopolysaccharide (LPS 10 ng ml(-1) LPS). The effect of NA was reversed by the selective beta-adrenoceptor antagonist propranolol (10 microM), but not by the alpha-adrenoceptor antagonist phentolamine (10 microM). In the concentration range of 10 nM-10 microM, isoproterenol, a beta-adrenoceptor agonist, but not phenylephrine (a selective alpha1-adrenoceptor agonist) or UK-14304 (a selective alpha2-adrenoceptor agonist) mimicked the inhibitory effects of catecholamines on MIP-1alpha production. Increases in intracellular cyclic adenosine monophosphate, elicited either by the selective type IV phosphodiesterase inhibitor rolipram (0.1 - 10 microM), or by prostaglandin E2, (10 nM-10 microM) decreased MIP-1alpha release, suggesting that increased cyclic AMP may contribute to the suppression of MIP-1alpha release by beta-adrenoceptor stimulation. Northern blot analysis demonstrated that NA (100 nM-10 microM), Ad, isoproterenol, as well as rolipram (100 nM-10 microM) decreased LPS-induced MIP-1alpha mRNA accumulation. NA and Ad (1-100 microM) also decreased MIP-1alpha production in thioglycollate-elicited murine peritoneal macrophages. Pretreatment of mice with either isoproterenol (10 mg kg(-1), i.p.) or rolipram (25 mg kg(-1), i.p.) decreased LPS-induced plasma levels of MIP-1alpha, while propranolol (10 mg kg(-1), i.p.) augmented the production of this chemokine, confirming the role of a beta-adrenoceptor mediated endogenous catecholamine action in the regulation of MIP-1alpha production in vivo. Thus, based on our data we conclude that catecholamines are important endogenous regulators of MIP-1alpha expression in inflammation.lld:pubmed
pubmed-article:9863660pubmed:languageenglld:pubmed
pubmed-article:9863660pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9863660pubmed:citationSubsetIMlld:pubmed
pubmed-article:9863660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9863660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9863660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9863660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9863660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9863660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9863660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9863660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9863660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9863660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9863660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9863660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9863660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9863660pubmed:statusMEDLINElld:pubmed
pubmed-article:9863660pubmed:monthNovlld:pubmed
pubmed-article:9863660pubmed:issn0007-1188lld:pubmed
pubmed-article:9863660pubmed:authorpubmed-author:ViziE SESlld:pubmed
pubmed-article:9863660pubmed:authorpubmed-author:SzabóCClld:pubmed
pubmed-article:9863660pubmed:authorpubmed-author:SalzmanA LALlld:pubmed
pubmed-article:9863660pubmed:authorpubmed-author:HaskóGGlld:pubmed
pubmed-article:9863660pubmed:authorpubmed-author:ShanleyT PTPlld:pubmed
pubmed-article:9863660pubmed:authorpubmed-author:NémethZ HZHlld:pubmed
pubmed-article:9863660pubmed:authorpubmed-author:EgnaczykGGlld:pubmed
pubmed-article:9863660pubmed:issnTypePrintlld:pubmed
pubmed-article:9863660pubmed:volume125lld:pubmed
pubmed-article:9863660pubmed:ownerNLMlld:pubmed
pubmed-article:9863660pubmed:authorsCompleteYlld:pubmed
pubmed-article:9863660pubmed:pagination1297-303lld:pubmed
pubmed-article:9863660pubmed:dateRevised2008-11-20lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:meshHeadingpubmed-meshheading:9863660-...lld:pubmed
pubmed-article:9863660pubmed:year1998lld:pubmed
pubmed-article:9863660pubmed:articleTitleExogenous and endogenous catecholamines inhibit the production of macrophage inflammatory protein (MIP) 1 alpha via a beta adrenoceptor mediated mechanism.lld:pubmed
pubmed-article:9863660pubmed:affiliationDepartment of Pharmacology, Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest.lld:pubmed
pubmed-article:9863660pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9863660lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9863660lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9863660lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9863660lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9863660lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9863660lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9863660lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9863660lld:pubmed